The Cancer Researcher
  • Home
  • About
  • The Cancer Researcher Podcast
  • #KeepResearchCurious
No Result
View All Result
  • Home
  • About
  • The Cancer Researcher Podcast
  • #KeepResearchCurious
No Result
View All Result
The Cancer Researcher
No Result
View All Result

The EACR’s Top 10 Cancer Research Publications: February 2022

October 17, 2025
EACR top 10 cancer research publications

The EACR’s Top 10 Cancer Research Publications is a regular summary of the most interesting and impactful recent papers in cancer research. It is curated by the Board of the European Association for Cancer Research (EACR).

The list below appears in no particular order, and the summary information has been provided by the authors.

Use the dropdown menu or ‘Previous’ and ‘Next’ buttons to navigate the list.

8. Multi-omic machine learning predictor of breast cancer therapy response

  • 1. Hepatic stellate cells suppress NK cell-sustained breast cancer dormancy
  • 2. Commensal bacteria promote endocrine resistance in prostate cancer through androgen biosynthesis
  • 3. Phase I/II Trial of Vemurafenib in Dogs with Naturally Occurring, BRAF-mutated Urothelial Carcinoma
  • 4. Dietary palmitic acid promotes a prometastatic memory via Schwann cells
  • 5. Acquired resistance to anti-MAPK targeted therapy confers an immune-evasive tumor microenvironment and cross-resistance to immunotherapy in melanoma
  • 6. Fasting-Mimicking Diet Is Safe and Reshapes Metabolism and Antitumor Immunity in Patients with Cancer
  • 7. Low neoantigen expression and poor T-cell priming underlie early immune escape in colorectal cancer
  • 8. Multi-omic machine learning predictor of breast cancer therapy response
  • 9. Pharmacologic Reduction of Mitochondrial Iron Triggers a Noncanonical BAX/BAK-Dependent Cell Death
  • 10. Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients
Previous
Next

Sammut, SJ., Crispin-Ortuzar, M., Chin, SF. et al. Nature 601, 623–629 (2022).

Summary of the findings

Despite great strides in understanding the biology of cancer, we still cannot reliably predict response to chemotherapy (plus HER2-targeted therapy for ERBB2 amplified tumours). In this study, we aimed to: (a) understand the biological processes associated with response to chemotherapy in breast cancer and (b) build a machine learning framework that combines pre-therapy molecular and digital pathology data to predict response.

We molecularly profiled breast tumour biopsies obtained at diagnosis from 168 women using exome and RNA sequencing and analysed their histological architecture using digital pathology. Women received 18 weeks of pre-operative chemotherapy and response was assessed at surgery using the Residual Cancer Burden score.

The baseline pre-therapy features were monotonically associated with response. DNA features associated with response related to genomic instability, including tumour mutation and neoantigen burden, homologous recombination deficiency and TP53 mutations. Response to therapy was also modulated by the tumour immune microenvironment. Specifically, high lymphocyte density, lack of T-cell dysfunction and exclusion, and absence of HLA class I loss of heterozygosity were associated with a better outcome.

Combining these molecular and digital pathology features into a multi-omic machine learning model predicted a pathological complete response in an external validation cohort with an area under curve of 0.87.

A tweetorial describing this study can be found at: https://twitter.com/stephensammut/status/1468251380586590216

Future impact of the findings

By integrating highly dimensional multi-omic data generated by profiling the tumour ecosystem, we have increased our understanding of the biology of breast cancer and developed a framework that will transform the way we treat it. In the future, this framework could be used to determine which patients can be treated with standard of care therapies (if they are predicted to respond) or treated using novel therapies in clinical trials (if predicted to be resistant to standard therapies). Perhaps more importantly, this approach has demonstrated a new way of thinking about forecasting therapy response which could be adapted for use in other cancer types.

Read more in Nature

8. Multi-omic machine learning predictor of breast cancer therapy response

  • 1. Hepatic stellate cells suppress NK cell-sustained breast cancer dormancy
  • 2. Commensal bacteria promote endocrine resistance in prostate cancer through androgen biosynthesis
  • 3. Phase I/II Trial of Vemurafenib in Dogs with Naturally Occurring, BRAF-mutated Urothelial Carcinoma
  • 4. Dietary palmitic acid promotes a prometastatic memory via Schwann cells
  • 5. Acquired resistance to anti-MAPK targeted therapy confers an immune-evasive tumor microenvironment and cross-resistance to immunotherapy in melanoma
  • 6. Fasting-Mimicking Diet Is Safe and Reshapes Metabolism and Antitumor Immunity in Patients with Cancer
  • 7. Low neoantigen expression and poor T-cell priming underlie early immune escape in colorectal cancer
  • 8. Multi-omic machine learning predictor of breast cancer therapy response
  • 9. Pharmacologic Reduction of Mitochondrial Iron Triggers a Noncanonical BAX/BAK-Dependent Cell Death
  • 10. Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients
Previous
Next
Tags: EACR Top Ten Cancer Research Publications

Related Posts

EACR keynote takes Erik Sahai to Nanchang, China for the CSCB’s Tumour Cell Biology conference

EACR keynote takes Erik Sahai to Nanchang, China for the CSCB’s Tumour Cell Biology conference

August 19, 2026

Erik Sahai, Principal Group Leader and Deputy Research Director at the Francis Crick Institute, travelled to Nanchang, China, this month to deliver an EACR keynote talk...

“Access to knowledge, workshops, events, networking opportunities and connections” – Nazha Ghaleb on the EACR member community

“Access to knowledge, workshops, events, networking opportunities and connections” – Nazha Ghaleb on the EACR member community

August 17, 2026

Nazha Ghaleb (who goes by Nana) has been an EACR member for over two years, and an EACR Ambassador for much of that time. A molecular...

“The Editorial Fellowship has strongly reinforced my decision to pursue this career path” – EACR member Amel Aziba’s experience on the Molecular Oncology editorial team

“The Editorial Fellowship has strongly reinforced my decision to pursue this career path” – EACR member Amel Aziba’s experience on the Molecular Oncology editorial team

August 12, 2026

EACR member Amel Aziba has now completed her EACR-Molecular Oncology Editorial Fellowship, funding that is awarded to enable a talented cancer researcher to gain knowledge and...

The Cancer Researcher EACR logo

About Us

The Cancer Researcher is an online magazine for the cancer research community from the European Association for Cancer Research.

The EACR, a registered charity, is a global community for those working and studying in cancer research. Our mission is “The advancement of cancer research for the public benefit: from basic research to prevention, treatment and care.”

Advertisement Advertisement Advertisement
ADVERTISEMENT

RECENT POSTS

Spotlight on the Serbian Association for Cancer Research (SDIR)
Community

Spotlight on the Serbian Association for Cancer Research (SDIR)

September 4, 2026
Spotlight on the Portuguese Association for Cancer Research (ASPIC)
Community

Spotlight on the Portuguese Association for Cancer Research (ASPIC)

August 27, 2026
The Cancer Researcher

© 2025 EACR

Navigate site

  • About
  • Privacy
  • Main EACR website

Follow us

No Result
View All Result
  • Home
  • About
  • The Cancer Researcher Podcast
  • #KeepResearchCurious

© 2025 EACR